What biomarker testing is recommended for metastatic Thyroid Cancer

Biomarker Testing for Metastatic Thyroid Cancer

I'll walk you through what testing doctors typically recommend when thyroid cancer has spread to distant sites, based on current clinical guidelines.

PRIMARY MONITORING BIOMARKERS

Thyroglobulin (Tg) and Thyroglobulin Antibodies (Tg ab)

According to the NCCN Guidelines for Thyroid Carcinoma, these are the cornerstone biomarkers for monitoring differentiated thyroid cancer:

• Thyroglobulin (Tg): This is a protein produced by thyroid cells. After thyroid removal, any detectable Tg suggests remaining thyroid tissue or cancer. Rising Tg levels over time are particularly concerning and may indicate disease progression.
• Thyroglobulin Antibodies (Tg ab): Some patients develop antibodies against thyroglobulin, which can interfere with Tg measurements. Testing for these antibodies is important because they can give false results if not accounted for.

The NCCN Guidelines emphasize that highly sensitive (second-generation) thyroglobulin assays should be used for accurate monitoring, especially in patients with metastatic disease.

SOMATIC MUTATION TESTING (Genetic Testing of the Cancer)

For patients with metastatic disease, the NCCN Guidelines recommend testing the cancer cells themselves for specific mutations that may guide treatment decisions:

Actionable mutations to test for include:

• BRAF V600E mutations – Found in some papillary thyroid cancers; may respond to targeted therapies like dabrafenib/trametinib
• RET gene fusions or mutations – Can be treated with RET inhibitors (selpercatinib or pralsetinib)
• ALK gene fusions – May respond to ALK inhibitors
• NTRK gene fusions – Can be treated with TRK inhibitors (larotrectinib, entrectinib, repotrectinib)
• DNA mismatch repair deficiency (dMMR) and microsatellite instability (MSI) – May indicate responsiveness to immunotherapy
• Tumor mutational burden (TMB) – High TMB may predict response to checkpoint inhibitors like pembrolizumab

According to the NCCN Guidelines, "If not already done, then somatic testing should be done to identify potentially actionable mutations."

IMAGING-BASED BIOMARKERS

Radioactive Iodine (RAI) Uptake Assessment

The NCCN Guidelines recommend diagnostic whole-body scans using Iodine-131 or Iodine-123 to determine if metastases are "iodine-avid" (able to take up radioactive iodine). This is critical because:

• Iodine-avid disease can be treated with radioactive iodine therapy
• Iodine-refractory disease (doesn't take up iodine) requires different treatment approaches like kinase inhibitors

HOW DOCTORS USE THIS INFORMATION

Clinical Reasoning: Doctors use these biomarkers together to:

1. Confirm metastatic disease is present
2. Determine if the cancer can be treated with radioactive iodine
3. Identify specific mutations that might respond to targeted drugs
4. Monitor treatment response over time
5. Detect early signs of disease progression

QUESTIONS TO ASK YOUR ONCOLOGY TEAM

1. "Have all my metastases been tested for mutations like BRAF, RET, ALK, and NTRK?" This ensures you know about all potential treatment options.

2. "What is my current thyroglobulin level, and how does it compare to previous measurements?" Understanding your Tg trend helps assess disease activity.

3. "Do my metastases take up radioactive iodine, or are they iodine-refractory?" This determines whether RAI therapy is an option for me.

4. "Based on my specific mutations and biomarkers, what treatment approaches do you recommend?" This helps you understand why your doctor is recommending a particular therapy.

5. "How often should my thyroglobulin and other biomarkers be monitored?" Monitoring frequency depends on your disease status and treatment.

6. "Are there any clinical trials available that target my specific mutations?" Clinical trials may offer access to newer therapies.

IMPORTANT CONTEXT

The NCCN Guidelines note that for patients with metastatic differentiated thyroid cancer that is RAI-refractory (doesn't respond to radioactive iodine), lenvatinib is the preferred systemic therapy option based on clinical trial data showing improved progression-free survival. However, your specific treatment will depend on your individual biomarker results, disease burden, and overall health.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.